UnitedHealthcare (UNH) Stock Analysis: Is It a Buy, Hold, or Sell?

PUBLISHED Sep 25, 2025, 5:14:24 PM        SHARE

img
imgIntrinsic Value Only on YouTube

Oh man, UnitedHealthcare stock. Year to date, shares are down 50%, wiping out roughly $254 per share in market value. Let’s unpack what’s driving the slide, explore the key financials, and see if this pullback masks a buying opportunity.

First off, UnitedHealth Group is a Minnesota‐based healthcare services and insurance titan. With a market cap of $226 billion, it’s one of the biggest players in U.S. healthcare. The company pays a reliable dividend yield of 3.54%, and the current PE ratio is the lowest it’s been since 2012.

The primary catalysts for the downturn are a Q2 earnings miss, a 2026 guidance cut, rising unit costs, and broader sector weakness. Tariff pressures under the current administration affect many large firms, but a handful of company-specific issues have hit UNH especially hard.

Q2 2025 Earnings and Guidance Revision

In Q2 2025, UnitedHealthcare reported adjusted EPS of $4.08, missing analyst forecasts of $4.48. Revenue inched up to $111 billion, but the earnings shortfall triggered a full-year EPS guidance cut to $16, down from prior targets in the high $29–30 range. A revision of that magnitude always rattles investor confidence.


Metric Q2 2025 Actual Q2 2025 Estimate
Adjusted EPS $4.08 $4.48
Revenue $111 billion
Full-Year EPS Guidance $16 $29–30

Pricing Power and Segment Performance

UnitedHealth leverages its massive membership base to push through price increases. Unit costs climbed a total of 89.4%, translating into a 4.3% higher average price hike than the previous year. However, the pharmacy benefit management business saw a 7% revenue decline, sparking questions over integration synergies from past acquisitions.


Measure Change
Unit Cost Increase 89.4%
Year-over-Year Price Hike 4.3%
Pharmacy Benefit Business Decline 7%

Regulatory Scrutiny and Leadership Shifts

Beyond the numbers, UNH is under federal civil and criminal investigations for alleged Medicare Advantage billing fraud. Potential settlements or fines could total around $1.6 billion. While manageable given existing cash reserves, the news has unsettled investors.

Leadership turnover adds another layer of uncertainty. Frequent CEO changes can erode investor trust, especially when the fate of prior executives looms large in memory.

Sector Weakness and Peer Performance

It’s not just UnitedHealth feeling the pain. The overall healthcare sector is at its weakest point in years. Companies like Pfizer, Moderna, and Johnson & Johnson are all down significantly, dragging sector ETFs and funds out of the group—even when fundamentals at individual firms remain intact.


Company YTD Performance
UnitedHealthcare (UNH) -50%
Pfizer (PFE) -25%
Moderna (MRNA) -30%
Johnson & Johnson (JNJ) -15%

Share Buybacks and Insider Confidence

One positive signal: UNH is aggressively buying back its own shares. Share repurchases often indicate management believes the stock is undervalued. Reducing the float can enhance EPS and return value to shareholders over time.

Historical Valuation Comparison

When you compare today’s valuation to historical levels, the case for buying becomes clearer. The PE ratio is at 13×—its lowest since 2012—while the share price is near 2019 lows. Yet, EPS levels remain close to all-time highs, creating a compelling value setup.


Year PE Ratio Low Share Price Low Adjusted EPS Guidance
2012 12×
2019 $249
2025 13× $254 $16

Calculating Intrinsic Value

Let’s run intrinsic value estimates using a conservative 6% growth assumption:

  • Graham Original Formula: $473
  • Graham Updated Formula: $420
  • Analyst-Adjusted Model: $266

UNH’s current share price of $249 sits below even the most conservative $266 estimate. Applying a 35% margin of safety yields a buy threshold near $273, leaving upside potential at current levels.


Valuation Model Intrinsic Value
Graham Original Formula $473
Graham Updated Formula $420
Analyst-Adjusted Model $266
35% Margin of Safety Level $273
Current Share Price $249

Balance Sheet Strength and Dividend Profile

On the balance sheet, assets comfortably exceed liabilities, and $1.6 billion in cash can absorb potential regulatory costs. The dividend yield of 3.54% equates to about $8 per share, with a payout ratio of 33%. Over the past five years, dividends grew at 13.64% annually, and they haven’t been cut in 15 years.

Still, if legal penalties escalate or cost pressures mount, a dividend reduction could occur. That scenario would likely push the stock lower before it rebounds.


Metric Value
Dividend Yield 3.54%
Annual Dividend per Share $8
Payout Ratio 33%
5-Year Dividend Growth Rate 13.64%
Consecutive Annual Increases 15 years

Final Verdict: Buy, Hold, or Sell?

With shares trading below intrinsic estimates, a low PE ratio, strong cash flows, and active share repurchases, the risk/reward profile tilts in favor of long-term buyers. Regulatory and sector headwinds introduce volatility, but the fundamental setup and valuation are attractive.

Investment Verdict: Buy



Sound investments
don't happen alone

Find your crew, build teams, compete in VS MODE, and identify investment trends in our evergrowing investment ecosystem. You aren't on an island anymore, and our community is here to help you make informed decisions in a complex world.

More Reads
Hims & Hers Stock Revisited: Is It Still a Buy?
Image

A little over a month ago, I covered Hims & Hers stock and rated it a buy on August 5, 2025. Since then, the share price has climbed nearly 29%, prompting a fresh look at this telehealth and wellness company’s valuation.

Colgate Palmolive Limited Stock Analysis – Technical & Fundamental Breakdown
Image

Hello everyone, I’m Kaneka. Today, I’ll be analyzing **Colgate Palmolive Limited**. We’ll look at both the **fundamental analysis** and the **technical chart patterns** of the stock.

Soundhound AI Stock Analysis: Growth, Innovation, and Valuation Concerns
Image

Soundhound AI is developing innovative artificial intelligence technology that has investors buzzing. The company recently reported **217% year-over-year revenue growth** in its most recent quarter, sparking questions about whether this stock is a hidden gem or an overhyped play. Let’s break down the company’s latest developments, its growth drivers, and the valuation picture to see where things stand.

Extra Space Storage (EXR) Stock Analysis: Dividend Growth, Performance, and Long-Term Outlook
Image

It’s not exactly difficult these days to find a company paying a 3–4% dividend yield. Plenty of names come to mind right away. But Extra Space Storage (NYSE: EXR) stands out because it doesn’t just pay a dividend—it has a long track record of consistent growth.

Dutch Bros Q2 Earnings Analysis: Revenue, Growth Strategy, and Stock Outlook
Image

We’re breaking down Dutch Bros’ Q2 earnings with the same energy and straight talk you expect. We’ll cover financial highlights, expansion trajectory, strategic initiatives, growth opportunities, risks, and wrap up with a clear buy/hold/sell verdict.

Texas Roadhouse (TXRH) Q2 2025 Earnings Deep Dive and Stock Outlook
Image

We’re breaking down Texas Roadhouse (TXRH), a midcap restaurant chain that reported a **strong** quarter 2, 2025. The brand’s casual‐dining concept has been firing on all cylinders, with momentum in both guest traffic and systemwide expansion. In this deep dive, we’ll cover the quarter’s revenue beat, margin pressure, unit growth and what it all means for potential investors.

Cisco Systems Earnings Breakdown: A Steady Player with AI Upside
Image

Hey everyone, welcome back to Stock Brock. Today we’re diving into Cisco Systems—a name I never thought I’d break down, but their recent **earnings** caught my attention. In this article, we’ll unpack the key numbers, explore growth drivers, weigh the risks, and I'll share whether Cisco stock deserves a spot in your portfolio.

Hormel Foods: A Defensive Staple at Multi-Year Lows
Image

Hormel Foods boasts more than **130 years** of history, anchored by a portfolio of well-known names that appear in pantries nationwide. From **Spam** to **Skippy**, **Applegate** to **Geno**, the company blends time-tested staples with newer offerings aimed at evolving tastes. ​

What Is Big Bear AI?
Image

**Big Bear AI** is a provider of AI-powered decision intelligence solutions for highly complex, distributed, mission-based environments. Organizations across defense, intelligence, logistics, enterprise operations, autonomous systems, and cybersecurity rely on its predictive analytics and AI capabilities.

Lucid Stock Update: Key Data Points & Market Moves
Image

Today, we’re diving into Lucid’s latest trading session, breaking down the numbers that moved the needle and outlining everything you need to know.

Altise Stock Valuation: Unpacking the DCF Model and Financial Health
Image

Welcome to my channel. I’m Scott, and today we’ll dive into valuing **Altise** stock by analyzing its financial statements and key ratios to decide if it’s a buy or a sell. This article covers the first half of our detailed walkthrough—stay tuned for part two.

Dollar Cost Averaging: My Apple Investing Strategy
Image

Are you ready to become a multi-millionaire with Apple? For the last two years, I’ve invested in Apple (AAPL) every single trading day. I started with $20 a day and, after a raise, bumped it up to $60 daily. This simple, repeatable method—called dollar cost averaging—is how I’m on track for an eight-figure nest egg by retirement.

The Wild High-Stakes Story of CoreWeave: Betting on the AI Gold Rush
Image

All right, so we’re in the middle of this massive AI gold rush, and everyone is scrambling to pick the one winning AI company. It feels like buying a lottery ticket—totally random and wildly risky. But what if there’s a smarter way to play? Instead of wagering on singular winners, you invest in the entire revolution. Welcome to the **picks and shovels** approach, and at the center of this strategy is CoreWeave.

A New Way to Look at Investing - Moderna in depth
Image

All right, today we’re diving into a completely fresh approach to investing—one that combines cutting-edge AI with tried-and-true fundamentals. And to illustrate this method, we’re zeroing in on a company almost everyone has on their radar: Moderna.

Content Creators, Join Now!
Image

StockBossup is a super friendly to content creator that provide stock analysis, financial literacy, and new investor guides!

The Power of Compound Interest: Earning Interest on Your Interest
Image

What if your money could grow not only on the dollars you invest today, but also on the interest those dollars generate tomorrow? That’s the magic of compound interest.

Next Fintech Stocks to Watch: Finding the Next SoFi
Image

Wouldn’t it be nice if we could rewind the clock one year and buy SoFi stock at around \$6 per share? Back then, signs of SoFi’s transformation into a profitable, growing fintech powerhouse were already visible. My co-host Julia and I decided to channel that energy into uncovering the **next SoFi**—a fintech gem with similar upside but still flying under the radar.

5 High-Quality Dividend Growth Stocks Still Trading at Attractive Levels
Image

As my favorite stock analyst, Chuck Carnival from FastGraphs, always says, it is a market of stocks—not a stock market. Today, I’ve dug into my watch list of top-tier dividend companies and filtered for valuation metrics like **price to earnings**, **price to free cash flow**, and **dividend yield theory**. After sifting through, here are five dividend growth stocks still trading at attractive levels.

Is Hershey a Value Trap or Sweet Opportunity?
Image

Why Hershey? Because it’s down crazy—over 9% in the past year—even though it’s basically the chocolate brand in the U.S. and globally recognized. You’d think being king of the chocolate aisle would insulate you, but nope. Cocoa prices are crashing the party.

Resources for Publishers
Resources for New Investors
Boosted with BossCoin
Top Investors
user_profile
Tom Hamilton
user_profile
Wise Intelligent
user_profile
Mark Robertson
user_profile
Kevin Matthews II
user_profile
Akeiva Ellis
user_profile
Brendan Dale
user_profile
Kenneth Chavis IV
user_profile
Sharita Humphrey